Quick Answer
Outlook Therapeutics, Inc. reported Total Revenue of $1.41 million for fiscal year 2025.
Outlook Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $1.41M | — | — | — | — | — |
| Revenue (ASC 606) | $1.41M | — | — | — | — | — |
| Net Income | -$62.42M +17.2% |
-$75.37M -27.8% |
-$58.98M +10.7% |
-$66.05M -24.2% |
-$53.16M -50.9% |
-$35.24M -2.1% |
| Diluted EPS | -$1.79 +55.9% |
-$4.06 +14.0% |
-$4.72 -1422.6% |
-$0.31 +11.4% |
-$0.35 +47.8% |
-$0.67 |
| Total Assets | $18.58M -35.5% |
$28.82M -10.8% |
$32.30M +13.2% |
$28.53M +25.1% |
$22.81M +15.6% |
$19.73M +15.2% |
| Cash and Equivalents | $8.08M -45.9% |
$14.93M -36.2% |
$23.39M +34.5% |
$17.40M +20.2% |
$14.48M +15.5% |
$12.54M +56.4% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | -$32.19M +56.0% |
-$73.08M -406.1% |
-$14.44M -265.3% |
$8.74M +89.6% |
$4.61M +63.0% |
$2.83M +117.5% |
| R&D Expense | $27.18M -34.9% |
$41.76M +57.9% |
$26.45M -37.5% |
$42.33M +8.7% |
$38.96M +47.9% |
$26.34M +10.7% |
| Operating Income | -$67.06M +6.5% |
-$71.70M -35.0% |
-$53.13M +15.8% |
-$63.07M -21.9% |
-$51.73M -40.4% |
-$36.84M -1.5% |
| Gross Profit | $57.2K | — | — | — | — | — |
| Shares Outstanding | 53.89M +125.4% |
23.91M +83.7% |
13.01M -94.3% |
227.31M +28.8% |
176.46M +38.7% |
127.18M +344.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2025 | $1.51M | — | +157.8% |
| Revenue (ASC 606) | June 30, 2025 | $1.51M | — | — |
| Net Income | December 31, 2025 | -$23.06M | -232.7% | -14.4% |
| Diluted EPS | December 31, 2025 | -$0.38 | -152.8% | +30.9% |
| Total Assets | December 31, 2025 | $18.24M | +7.2% | -1.9% |
| Cash and Equivalents | December 31, 2025 | $8.68M | +52.2% | +7.4% |
| Long-Term Debt | June 30, 2019 | $62.9K | -43.6% | -16.3% |
| Stockholders Equity | December 31, 2025 | -$38.55M | +23.3% | -19.8% |
| R&D Expense | December 31, 2025 | $3.63M | -62.4% | -49.1% |
| Operating Income | December 31, 2025 | -$13.48M | +37.6% | +14.4% |
| Gross Profit | December 31, 2025 | -$1.24M | — | -216.1% |
| Shares Outstanding | December 31, 2025 | 64.56M | +159.2% | +19.8% |
- Outlook Therapeutics, Inc. reported Total Revenue of $1.41 million for fiscal year 2025.
- Outlook Therapeutics, Inc. showed a decrease of -82.6% in Total Revenue compared to the prior fiscal year.
- Outlook Therapeutics, Inc. reported Revenue (ASC 606) of $1.41 million for fiscal year 2025.
- Outlook Therapeutics, Inc. reported Net Income of -$62.42 million for fiscal year 2025.
- Outlook Therapeutics, Inc. showed an increase of +17.2% in Net Income compared to the prior fiscal year.
- Outlook Therapeutics, Inc. reported Diluted EPS of $1.79 per share (loss) for fiscal year 2025.
- Outlook Therapeutics, Inc. showed an increase of +55.9% in Diluted EPS compared to the prior fiscal year.
- Outlook Therapeutics, Inc. reported Total Assets of $18.58 million for fiscal year 2025.
- Outlook Therapeutics, Inc. showed a decrease of -35.5% in Total Assets compared to the prior fiscal year.
- Outlook Therapeutics, Inc. reported Cash and Equivalents of $8.08 million for fiscal year 2025.
- Outlook Therapeutics, Inc. showed a decrease of -45.9% in Cash and Equivalents compared to the prior fiscal year.
- Outlook Therapeutics, Inc. reported Long-Term Debt of $50.3 thousand for fiscal year 2019.
- Outlook Therapeutics, Inc. showed a decrease of -48.9% in Long-Term Debt compared to the prior fiscal year.
- Outlook Therapeutics, Inc. reported Stockholders Equity of -$32.19 million for fiscal year 2025.
- Outlook Therapeutics, Inc. showed an increase of +56.0% in Stockholders Equity compared to the prior fiscal year.
- Outlook Therapeutics, Inc. reported R&D Expense of $27.18 million for fiscal year 2025.
- Outlook Therapeutics, Inc. showed a decrease of -34.9% in R&D Expense compared to the prior fiscal year.
- Outlook Therapeutics, Inc. reported Operating Income of -$67.06 million for fiscal year 2025.
- Outlook Therapeutics, Inc. showed an increase of +6.5% in Operating Income compared to the prior fiscal year.
- Outlook Therapeutics, Inc. reported Gross Profit of $57.2 thousand for fiscal year 2025.
- Outlook Therapeutics, Inc. reported Shares Outstanding of 53.89 million shares for fiscal year 2025.
- Outlook Therapeutics, Inc. showed an increase of +125.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: